• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BBBT
Share

Black Bird Biotech, Inc. Stocks

$ 0Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 98405

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Black Bird Biotech Inc. operates within the biotechnology sector, offering a diverse array of products. A key offering is MiteXstream, a unique plant-derived biopesticide manufactured and distributed by the company, specifically formulated to eradicate spider mites. The company further diversifies its portfolio with a range of consumer goods sold under its Grizzly Creek Naturals brand. These include CBD oils, gummies, and pet treats, as well as CBD-infused personal care items and both gel and spray hand sanitizer products. Beyond these offerings, Black Bird Biotech also engages in the cultivation of industrial hemp, participating in the Montana Hemp pilot program. The entity, headquartered in Flower Mound, Texas, underwent a name change in June 2021, transitioning from its former identity as Digital Development Partners, Inc. to its current Black Bird Biotech, Inc. designation.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 17:26

The AI bubble has burst in the world's second-largest stock market. What triggered it?

27.10.2026 17:18

Nvidia will invest $3 billion in Meta stock. The companies will expand their work on AI agents

27.10.2026 16:57

Revolut Is Under Scrutiny Again Due to Its Rapid Product Rollouts — FT

27.10.2026 16:50

"Investors Are Taking Out Their Frustration": PagSeguro's Fintech Shares Have Plummeted. Is It Time to Buy?

27.10.2026 15:53

Tefal's owner is returning to profitability. How will this affect its stock?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026